A Preliminary Bibliography on Injection Drug Use and Users (IDU) in ...
A Preliminary Bibliography on Injection Drug Use and Users (IDU) in ...
A Preliminary Bibliography on Injection Drug Use and Users (IDU) in ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
S<strong>IDU</strong>). Of the <strong>IDU</strong>, 77 were male; mean age: 30 years, mean ageat first <strong>in</strong>jecti<strong>on</strong>: 22 years (range 12-47); 50% had been us<strong>in</strong>g <strong>in</strong>jecti<strong>on</strong> drugs for atleast <strong>on</strong>e year; 33% had used <strong>in</strong>jecti<strong>on</strong> drugs with<strong>in</strong> the past 6 m<strong>on</strong>ths; 80% hadever used coca<strong>in</strong>e. Seroprevalence of HIV was 5% (5/92), HBV core antibody23% (21/91) <strong>and</strong> HCV antibody 47% (43/92). Am<strong>on</strong>g S<strong>IDU</strong>, 48 were males, meanage: 27 yrs. Over 1/2 did not know their sexual partners were <strong>IDU</strong>s at the time oftheir encounter. Pers<strong>on</strong>s were less likely to use c<strong>on</strong>doms c<strong>on</strong>sistently with theircasual <strong>IDU</strong> sex partners than with their casual n<strong>on</strong>-<strong>IDU</strong> sex partners (68% neverused c<strong>on</strong>doms with their casual <strong>IDU</strong> partners, 50% never used c<strong>on</strong>doms withtheir casual n<strong>on</strong>-<strong>IDU</strong> partners). Seroprevalence of HIV antibody was 1% (1/80),HBV core antibody 5% (4/80) <strong>and</strong> HCV antibody 1% (1/80). CONCLUSION: Inour study of a semi-rural populati<strong>on</strong>, we found behaviours <strong>and</strong> seroprevalencerates c<strong>on</strong>sistent with those found <strong>in</strong> urban <strong>and</strong> <strong>in</strong>ner-city populati<strong>on</strong>s. Theexistence of HIV, HBV <strong>and</strong> HCV <strong>in</strong> our surveyed populati<strong>on</strong> dem<strong>on</strong>strates<strong>on</strong>go<strong>in</strong>g high risk behaviours am<strong>on</strong>g <strong>IDU</strong> <strong>and</strong> S<strong>IDU</strong>. Both risk groups reportedrisky behaviours which <strong>in</strong>dicates the potential for c<strong>on</strong>t<strong>in</strong>ued transmissi<strong>on</strong> ofthese pathogens <strong>in</strong> this community.Vancouver-Richm<strong>on</strong>d Health Board . Harm Reducti<strong>on</strong>. 1998. Vancouver, BC:Vancouver-Richm<strong>on</strong>d Health Board.Vancouver -Richm<strong>on</strong>d Health Board . Reduc<strong>in</strong>g Harm: C<strong>on</strong>sider<strong>in</strong>g the Role of SafeInjecti<strong>on</strong> Sites - (draft). 1999. Vancouver, Vancouver/Richm<strong>on</strong>d Health Board.Vancouver-Richm<strong>on</strong>d Health Board: Work<strong>in</strong>g Committee . HIV/AIDS <strong>and</strong> <strong>in</strong>jecti<strong>on</strong>drug use <strong>in</strong> the DTES.Whynot E . Canadian Community Epidemiology Network <strong>on</strong> <strong>Drug</strong> <strong>Use</strong>. 1995.Vancouver, Vancouver Health Board.Whynot E . Vancouver CCENDU. A Canadian Community Epidemiology Network <strong>on</strong><strong>Drug</strong> <strong>Use</strong> Report. 1998.Willms SM, Michael V. Hayes, Hulchanski JD . Hous<strong>in</strong>g for Pers<strong>on</strong>s with HIV Infecti<strong>on</strong><strong>in</strong> Canada: Issues <strong>and</strong> Recommendati<strong>on</strong>s. CHS Research Bullet<strong>in</strong> [1-8]. 1991.Zou S, Tepper M, Giulivi A . Canada Communicable Disease Report: Hepatitis C <strong>in</strong>Canada . Viral Hepatitis <strong>and</strong> Emerg<strong>in</strong>g Bloodborne Pathogens <strong>in</strong> Canada. 2001.
Change language